KYKOF - Expanded use of Crysvita in bone-softening disorder Ok'd in Europe

The European commission has approved Kyowa Kirin' (KYKOF) Crysvita (burosumab) for use in older adolescents and adults patients with rare disease X-linked hypophosphataemia ((XLH)), an inherited disorder characterized by low levels of phosphate in the blood leading to soft and weak bones (rickets)CRYSVITA was previously approved for XLH with radiographic evidence of bone disease in children one year of age and older and adolescents with growing skeletons. Kyowa Kirin is developing the med in collaboration with Ultragenyx.

For further details see:

Expanded use of Crysvita in bone-softening disorder Ok'd in Europe